Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC5A2 | P31639 | 20/20 | 0.67 |
| ▸ | SLC5A1 | P13866 | 11/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Water SCHEMBL1566813 | 0.99 | SLC5A2 (0.65) | SLC5A2SLC5A1 | |
| SCHEMBL2971079 | 0.91 | SLC5A2 (0.58) | SLC5A2SLC5A1 | |
| SCHEMBL2972152 | 0.91 | SLC5A1 (0.60) | SLC5A2SLC5A1 | |
| SCHEMBL2975583 | 0.90 | SLC5A2 (0.67) | SLC5A2SLC5A1 | |
| SCHEMBL2964152 | 0.89 | SLC5A2 (0.59) | SLC5A2SLC5A1 | |
| SCHEMBL2973295 | 0.88 | SLC5A2 (0.60) | SLC5A2SLC5A1 | |
| SCHEMBL2975989 | 0.88 | SLC5A2 (0.60) | SLC5A2SLC5A1 | |
| SCHEMBL2969456 | 0.88 | SLC5A2 (0.78) | SLC5A2SLC5A1 | |
| SCHEMBL2968705 | 0.87 | SLC5A2 (0.61) | SLC5A2SLC5A1 | |
| SCHEMBL1316174 | 0.87 | SLC5A2 (0.62) | SLC5A2SLC5A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3072897-B1 | SPIROKETAL DERIVATIVES AND USE THEREOF AS DIABETIC MEDICINE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-06-26 | — | — | EP | claimed |
| EP-3072897-A1 | SPIROKETAL DERIVATIVES AND USE THEREOF AS DIABETIC MEDICINE | Chugai Seiyaku Kabushiki Kaisha (JP) | 2016-09-28 | — | — | EP | claimed |
| EP-1852439-B1 | SPIROKETAL DERIVATIVE AND USE THEREOF AS DIABETIC MEDICINE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2016-03-23 | — | — | EP | claimed |
| US-7767651-B2 | Spiroketal derivatives and use thereof as diabetic medicine | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-03 | — | — | US | claimed |
| US-20090030006-A1 | SPIROKETAL DERIVATIVES AND USE THEREOF AS DIABETIC MEDICINE | CHUGAI SEIYAYAKU KABUSHIKI KAISHA | 2009-01-29 | — | — | US | claimed |
| EP-1852439-A1 | SPIROKETAL DERIVATIVE AND USE THEREOF AS DIABETIC MEDICINE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-07 | — | — | EP | claimed |
| EP-3170834-B1 | CRYSTALLINE FORMS OF (1S,3'R,4'S,5'S,6'R)-6-[(4-ETHYLPHENYL)METHYL]-3',4',5',6'-TETRAHYDRO-6'-(HYDROXYMETHYL)SPIRO[ISOBENZOFURAN-1(3H) 2'-[2H]PYRAN]-3',4',5'-TRIOL | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2022-02-09 | — | — | EP | disclosed |
| US-10398653-B2 | Solid preparations containing tofogliflozin and process of producing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-09-03 | — | — | US | disclosed |
| EP-3072897-B1 | SPIROKETAL DERIVATIVES AND USE THEREOF AS DIABETIC MEDICINE | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2019-06-26 | — | — | EP | disclosed |
| US-20190151248-A1 | SOLID PREPARATIONS CONTAINING TOFOGLIFLOZIN AND PROCESS OF PRODUCING THE SAME | KOWA COMPANY, LTD. (JP) | 2019-05-23 | — | — | US | disclosed |
| EP-3482748-A1 | SOLID PREPARATIONS CONTAINING TOFOGLIFLOZIN AND METHOD FOR PRODUCING THE SAME | Chugai Seiyaku Kabushiki Kaisha (JP) | 2019-05-15 | — | — | EP | disclosed |
| US-10231930-B2 | Solid preparations containing tofogliflozin and process of producing the same | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2019-03-19 | — | — | US | disclosed |
| EP-3087989-B1 | SOLID PREPARATIONS COMPRISING TOFOGLIFLOZIN AND METHOD FOR PRODUCING THE SAME | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2018-12-19 | — | — | EP | disclosed |
| US-8569520-B2 | Crystal of spiroketal derivatives and process for preparation of spiroketal derivatives | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2013-10-29 | — | — | US | disclosed |
| WO-2012115249-A1 | CRYSTAL OF SPIROKETAL DERIVATIVE | 中外製薬株式会社 (JP) | 2012-08-30 | — | — | WO | disclosed |
| US-20110306778-A1 | CRYSTAL OF SPIROKETAL DERIVATIVES AND PROCESS FOR PREPARATION OF SPIROKETAL DERIVATIVES | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2011-12-15 | — | — | US | disclosed |
| EP-2308886-A1 | CRYSTAL OF SPIROKETAL DERIVATIVE, AND PROCESS FOR PRODUCTION THEREOF | Chugai Seiyaku Kabushiki Kaisha (JP) | 2011-04-13 | — | — | EP | disclosed |
| US-7767651-B2 | Spiroketal derivatives and use thereof as diabetic medicine | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2010-08-03 | — | — | US | disclosed |
| US-20090030006-A1 | SPIROKETAL DERIVATIVES AND USE THEREOF AS DIABETIC MEDICINE | CHUGAI SEIYAYAKU KABUSHIKI KAISHA | 2009-01-29 | — | — | US | disclosed |
| EP-1852439-A1 | SPIROKETAL DERIVATIVE AND USE THEREOF AS DIABETIC MEDICINE | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2007-11-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110306778-A1 | CRYSTAL OF SPIROKETAL DERIVATIVES AND PROCESS FOR PREPARATION OF SPIROKETAL DERIVATIVES | KLK6, WNK1, WNK3 | SLC5A2 1685/4885SLC5A1 1607/4885 |
| US-20190151248-A1 | SOLID PREPARATIONS CONTAINING TOFOGLIFLOZIN AND PROCESS OF PRODUCING THE SAME | SLC5A2, SLC5A1, SOST | SLC5A2 1/4885SLC5A1 2/4885 |
| US-20090030006-A1 | SPIROKETAL DERIVATIVES AND USE THEREOF AS DIABETIC MEDICINE | SLC5A1, NR3C2, NR5A1 | SLC5A2 6/4885SLC5A1 1/4885 |
| US-10398653-B2 | Solid preparations containing tofogliflozin and process of producing the same | SLC5A2, SLC5A1, SOST | SLC5A2 1/4885SLC5A1 2/4885 |
| US-10231930-B2 | Solid preparations containing tofogliflozin and process of producing the same | SLC5A2, SLC5A1, SOST | SLC5A2 1/4885SLC5A1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.